CENTOGENE Receives French Research Tax Credit Accreditation

Partners able to claim up to 30% tax relief

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France. Accordingly, it has received accreditation under the French R&D tax credit initiative ('Crédit d'Impôt Recherche', CIR) for a three-year period.

The CIR initiative enables eligible research-based companies, who are subject to corporate tax in France, to claim tax relief on 30% of all costs (up to €100 million) incurred in R&D activities outsourced to CENTOGENE.

Prof. Peter Bauer, Chief Medical & Genomic Officer at CENTOGENE, stated, “'We are excited to receive this accreditation as it recognizes our advanced research capabilities that we support our customers with. By lowering overall R&D costs, we will be able to support our current and future partners in generating novel insights and delivering data-driven, life-changing answers to rare and neurodegenerative disease patients.”

To learn more about the CIR initiative, visit: https://link.centogene.com/cir

About CENTOGENE

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 800,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 285 peer-reviewed publications.